Treating Schizophrenia by Correcting Abnormal Brain Development

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to determine whether treatment with tiagabine (Gabitril) during the early course of schizophrenia can fundamentally correct the brain deficits associated with the disease. This study is funded by the National Institutes of Health.

Clinical Trial Description

It is hypothesized that enhancement of GABA neurotransmission during the early course of the illness by tiagabine (Gabitril), a GABA transporter GAT-1-specific inhibitor and a FDA-approved anticonvulsant, will improve both clinical symptoms and working memory in schizophrenia. This improvement is postulated to be the result of tiagabine-mediated modification of the developmental synaptic pruning of prefrontal cortical circuitry. The occurrence of circuitry modification after tiagabine treatment will be assessed by the following independent methodologic approaches: MRI morphometric analysis of prefrontal gray matter volume and fMRI measurements of brain activity patterns during performance of tasks that probe working memory. ;

Study Design

Related Conditions & MeSH terms

Schizophrenia

Clinical Trial Details

NCT number	NCT00179465
Study type	Interventional
Source	Beth Israel Deaconess Medical Center
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	November 2003
Completion date	September 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05039489` - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia	N/A
Completed	`NCT05111548` - Brain Stimulation and Cognitive Training - Efficacy	N/A
Completed	`NCT05321602` - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder	Phase 1
Completed	`NCT04503954` - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia	N/A
Completed	`NCT02831231` - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium	Phase 1
Completed	`NCT05517460` - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center	N/A
Completed	`NCT03652974` - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy	Phase 4
Recruiting	`NCT04012684` - rTMS on Mismatch Negativity of Schizophrenia	N/A
Recruiting	`NCT04481217` - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia	N/A
Completed	`NCT00212784` - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)	Phase 3
Completed	`NCT04092686` - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia	Phase 3
Completed	`NCT01914393` - Pediatric Open-Label Extension Study	Phase 3
Recruiting	`NCT03790345` - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics	Phase 2/Phase 3
Recruiting	`NCT05956327` - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training	N/A
Terminated	`NCT03209778` - Involuntary Memories Investigation in Schizophrenia	N/A
Terminated	`NCT03261817` - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders	N/A
Completed	`NCT02905604` - Magnetic Stimulation of the Brain in Schizophrenia or Depression	N/A
Recruiting	`NCT05542212` - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia	N/A
Completed	`NCT04411979` - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia	N/A
Terminated	`NCT03220438` - TMS Enhancement of Visual Plasticity in Schizophrenia	N/A